Oropharyngeal cancer refers to a type of head and neck cancer that affects the back of the throat, including the base of the tongue and the tonsils. Some key advantages of oropharyngeal cancer diagnostics and treatment include early detection of cancers, targeted treatment options, and minimally invasive surgical procedures. The growing burden of HPV-positive oropharyngeal cancers globally is fueling extensive research on innovative diagnostic tests and therapeutics.
The oropharyngeal cancer market is estimated to be valued at USD 2.11 Bn in 2024 and is expected to reach USD 3.05 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Key Takeaways
Key players: Key players operating in the oropharyngeal cancer market are Bristol-Myers Squibb, Merck, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., AstraZeneca, Teva Pharmaceutical Industries Ltd., AB Science, Novartis.
Key opportunities: Increasing research on HPV-positive oropharyngeal cancers, emerging biomarkers for early detection, growth opportunities in developing countries.
Global expansion: Major players are focusing on expansion in Asia Pacific and Latin America owing to large patient pools and growing healthcare expenditure.
Market drivers: Increasing prevalence of HPV-induced Oropharyngeal Cancer globally is a major growth driver for this market. According to research, the prevalence of HPV-positive oropharyngeal cancer in the United States increased from 16.3% in 1984 to 72.7% in 2019.
PEST Analysis
Political: In some regions, healthcare policies and regulations affect funding and access to treatment options for oropharyngeal cancer patients.
Economic: Economic conditions influence research and development budgets for new drug treatments as well as patients' ability to afford different options.
Social: Social trends like changing risk factors can impact the occurrence of oropharyngeal cancer cases over time. Public awareness campaigns may influence screening and early detection rates.
Technological: Advancements in diagnostic tools and precision oncology approaches are improving outcomes. Targeted therapies and immunotherapy are enhancing survival while minimizing side effects compared to traditional chemotherapy or radiation.
Geographical Regions of Concentration
The highest incidence rates of oropharyngeal cancer are found in North America, Northern and Western Europe, Australia, and New Zealand. Within these regions, the United States accounts for a large portion of the total number of new cases and deaths each year. This is likely due to risk factors historically being more prevalent in these areas. However, incidence patterns are shifting as exposure trends change worldwide.
Fastest Growing Region
Parts of Asia, Africa, and Latin America are projected to see substantial growth in oropharyngeal cancer burden over the coming decades. This is linked to expansions in populations at risk combined with adoption of unhealthy lifestyle habits. India in particular is facing rising disease trends as prevention efforts have yet to curb behaviors linked to higher risks like tobacco use. Screening programs also need strengthening to catch cases early in many developing Asian and African countries.
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)